Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring

Summary

This is a prospective, monocentric diagnostic study aiming to evaluate whether a sedation score obtained by a per-procedural electroencephalogram (EEG), the PSI score, could identify patients for whom a 2 μg/kg dose of DEX would not be sufficient for the successful performance of cerebral NMRI, and who could therefore benefit from a higher dosage of DEX (4 μg/kg).

Eligibility

Inclusion Criteria:

* Indication of DEX sedation for brain NMRI at the CHR de Metz-Thionville

  * in a patient aged between 12 months and 5 years or
  * for a patient aged between 5 and 18 whose cooperation during the examination appears compromised (previous failure, autism spectrum disorders, etc.).
* Membership of a social security scheme
* Free and informed consent obtained from the patient's legal guardian(s).

Exclusion Criteria:

* Weight \< 10 kg
* Patients with contraindications to the use of DEX

  * Hypersensitivity to the active ingredient or to any of the excipients listed in the section on "Hypersensitivity".
  * Advanced heart block (level 2 or 3), unless pacemaker implanted
  * Uncontrolled hypotension
  * Acute cerebrovascular pathologies
* Patients with nasal obstruction
* Parental refusal of DEX administration
* Minors under guardianship
* Minors under judicial sanction

Conditions3

Browse More Trials